Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?

Table 4 Clinical efficacy of fulvestrant after progression on prior endocrine therapy with AIs

Study [ref.]	Treatment (setting)	Prior systemic treatments	Number of	Clinical benefit^a (%)
Perey et al. [93]	Fulvestrant (third line)	Include tamoxifen and AIs	67	28
Ingle et al. [92]	Fulvestrant (second and third line)	Prior nonsteroidal AIs, and tamoxifen in 79% of patients	77	29
Petruzelka and Zimovjanova [94]	Fulvestrant (second to fifth line)	Include nonsteroidal AIs, adjuvant tamoxifen, and goserelin formestane	44	52
Franco et al. [91]	Fulvestrant (mean prior endocrine therapies = 3.4)	Include nonsteroidal AIs, tamoxifen, megestrol acetate, exemestane, and chemotherapy	42	19
Steger et al. [95]	Fulvestrant (second to fifth line)	Include nonsteroidal AIs, tamoxifen, exemestane, goserelin, and formestane	88	57

Phase II clinical trials with fulvestrant following disease progression on prior endocrine therapy with aromatase inhibitors are summarized. ^aClinical benefit included patients who had a complete response, partial response, or stable disease for 24 weeks or longer. AI, aromatase inhibitor.

ISSN: 1465-542X